Harvard BioscienceHBIO
About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Employees: 416
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5.45% less ownership
Funds ownership: 73.39% [Q2] → 67.95% (-5.45%) [Q3]
7% less funds holding
Funds holding: 100 [Q2] → 93 (-7) [Q3]
13% less capital invested
Capital invested by funds: $90.9M [Q2] → $79.3M (-$11.5M) [Q3]
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
92% less call options, than puts
Call options by funds: $2K | Put options by funds: $26K
Research analyst outlook
We haven’t received any recent analyst ratings for HBIO.
Financial journalist opinion
Based on 3 articles about HBIO published over the past 30 days
